The global non-vascular stents market was worth US$ 1,024 million in 2023 and is anticipated to reach a valuation of US$ 1,658 million by 2032 from US$ 1,080 million in 2024, and it is predicted to register a CAGR of 5.5% during the forecast period 2024-2032.
As per the American Cancer Society, 1.9 million new cancer cases and 609360 cancer deaths are expected in the United States in 2022. The growing number of people suffering from urological and gastrointestinal diseases and the increasing application of non-vascular stents in various emerging fields, such as ophthalmic and neural sciences, are further expected to promote the growth of non-vascular stents. The rising demand for less invasive techniques decreases hospital stays, and diminishing the threat of contracting hospital-acquired infections propels the market growth. In the United States, kidney disorders kill more people than prostate or breast cancer each year. An estimated 34500 people die from prostate cancer yearly in the United States, whereas approximately 43780 die from breast cancer. The growing adoption of the latest technologies to develop stents and retrieval, growing demand for minimally invasive surgeries, and patients due to less cost and less procedural time amid the ambulatory surgical centers are projected to boost the growing demand for non-vascular stents market growth. More than 1 million abdominal wall hernia repairs are implemented annually in the U.S., with inguinal hernias representing around 77,000 cases. About 90% of inguinal hernia repairs are executed in males. As per WHO, 3 million people and above die yearly from chronic obstructive pulmonary diseases (COPD) worldwide, and 90% of the deaths are from low and middle-income countries.
In addition, the growing adoption of technological advancements in the healthcare sector, YOY growth in the geriatric population, and increased life expectancy are anticipated to boost the market’s growth rate during the forecast period. According to the World Health Organization (WHO), one in every six people is expected to be older than 60 or more by 2030. As a result, the aging population is likely to get diagnosed with various diseases, which is anticipated to result in a greater need for non-vascular stents.
However, stringent regulatory systems and high costs associated with non-vascular stents are expected to limit the adoption and negatively impact market growth. In addition, the availability of alternative options for relieving luminal structures further limits the market’s growth rate.
REPORT METRIC |
DETAILS |
Market Size Available |
2023 to 2032 |
Base Year |
2023 |
Forecast Period |
2024 to 2032 |
CAGR |
5.5% |
Segments Covered |
By Type, End User, Material, and Region. |
Various Analyses Covered |
Global, Regional, and country-level analysis; Segment-Level Analysis, DROC; PESTLE Analysis; Porter’s Five Forces Analysis, Competitive Landscape; Analyst Overview of Investment Opportunities |
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
Market Leaders Profiled |
CONMED Corporation, Taewoong Medical Co., Medtronic; C. R. Bard, Inc.; Boston Scientific Corporation; HOBBS MEDICAL, INC; Cook Medical; ELLA - CS, s.r.o.; Ltd.; Synchron Med Inc.; and Glaukos Corporation., and Others. |
The gastrointestinal stents segment is expected to dominate the non-vascular stents market with the largest share during the forecast period. The segment's growth is driven by the growing incidence of gastrointestinal cancer, such as stomach cancer, small intestine, bowels, and liver, integrated with patients' climbing significance for minimally invasive surgeries.
The ureteral stents segment is expected to grow rapidly owing to the rising incidence of ureteral diseases, urinary tract infections, and prostate cancers worldwide. In addition, thee. The increasing number of ureteroscopy, lithotripsy, and other techniques worldwide augment the growth of the ureteral stents segment.
The hospital end-user segment is predicted to dominate the global non-vascular stents market during the forecast period. The increasing number of patients suffering from ureteral, gastrointestinal, and other chronic diseases is climbing the market growth. Moreover, the well-developed healthcare infrastructure, expanding sound knowledge among the patients regarding the patients' early diagnosis and treatment, bolsters the market growth.
The metallic stents segment holds the largest share in the non-vascular stents market during the forecast period. The escalating technology advancements are significantly driving factors in usage and wide applications of metallic stents coupled with advanced technologies surge the market growth expansion during the analysis period.
The non-metallic stents segment is the quickest-growing segment and is scheduled to record the highest CAGR growth rate during the period. The non-metallic stents, used for treating benign structures as they require less treatment time, less cost, and easy movement, make the market move forward.
North America held a significant share in the global market in 2023 and the domination of the North American region in the global market is likely to be see during the forecast period owing to the increasing prevalence of lung cancer, glaucoma, central airway obstruction, COPD, asthma, and other chronic diseases in the U.S. and Canada. In addition, the local presence of major market players, the target population, and the robust healthcare infrastructure in the region further supported this region's dominance.
Europe is also expected to hold a substantial market share during the forecast period due to the flourishing medical technology sector and the increasing prevalence of gastric cancer in the EU5 countries.
On the other hand, the Asia-Pacific is expected to register a higher CAGR over the forecast period compared to other regions due to favorable government initiatives for using such medical devices, the rising geriatric population, and increasing healthcare expenditure.
Regions such as Latin America and MEA are expected to witness a steady CAGR during the forecast period.
Companies playing a leading role in the global non-vascular stents market profiled in this report are CONMED Corporation, Taewoong Medical Co., Medtronic; C. R. Bard, Inc.; Boston Scientific Corporation; HOBBS MEDICAL, INC; Cook Medical; ELLA - CS, s.r.o.; Ltd.; Synchron Med Inc.; and Glaukos Corporation.
By Type
By End User
By Material
By Region
Frequently Asked Questions
Yes, we have studied and included the COVID-19 impact on the global non-vascular stents market in this report.
North America captured the major share of the global market in 2023.
CONMED Corporation, Taewoong Medical Co., Medtronic; C. R. Bard, Inc.; Boston Scientific Corporation; HOBBS MEDICAL, INC; Cook Medical; ELLA - CS, s.r.o.; Ltd.; Synchron Med Inc.; and Glaukos Corporation are some of the key players in the non-vascular stents market.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region